5 Best Stem Cell Therapy Stocks to Buy

In this article, we will list the 5 Best Stem Cell Therapy Stocks to Buy. If you wish to see the methodology behind the article and the extended list, please visit 8 Best Stem Cell Therapy Stocks to Buy.

A scientist in a lab coat looking through a microscope at a petri dish of hematopoietic stem cells.

5. Amgen Inc. (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best stem cell therapy stocks to buy. Canaccord initiated coverage of Amgen Inc. (NASDAQ:AMGN) with a Hold rating on April 21, setting a price target of $366. The firm told investors in a research note that the company has executed well on its key growth drivers, but this is reflected in the stock’s good performance since last October. It further stated that it believes Amgen Inc.’s (NASDAQ:AMGN) current valuation to be appropriate, adding that meaningful appreciation from here “could be more challenging” because of some loss of exclusivities and pricing pressure across several of its large mature products.

For additional perspective, in its fiscal Q4 and full year 2025 results, Amgen Inc. (NASDAQ:AMGN) reported strong performance in the full year with double-digit growth in revenues and EPS. Total revenues for fiscal Q4 rose 9% to $9.9 billion compared to the prior year period, with product sales growing 7%, driven by 10% volume growth. Total revenues for the full year reached $36.8 billion, up 10% compared to the same quarter last year.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.